| DECLARATION FOR | ATTORNEY'S DOCKET NUMBER | | | |
|---|---|---|---|---|
| (Includes Reference to P | PCT International Applications | | 342312003700 | |
| | | | • | |
| | | | • | |
| | ntor I hereby declare that: | | | |
| | s, post office addresses and cit | • | • | |
| We believe w invention enti | | ventors of the subject matter v | which is claimed and for | which a patent is sought on the |
| CY | CLIC PEPTIDE ANTIFUNGA | • | a a a | |
| the specificati | on of which (check only one it | em below): | • | |
| | is attached hereto. | | | · · · · · · · · · · · · · · · · · · · |
| · | was filed as United States ap | oplication | | |
| ı | Serial No. | | | |
| | on | Compliantle) | | • |
| | and was amended on (i | | | 1.3 |
| × | was filed as PCT internation | • • | | |
| | Number PCT/US99/299 on December 15, 1999 and was amended under | | | |
| | on (if applicable). | | • | |
| | nte that we have reviewed and in amendment referred to abo | | above-identified specifi | ication, including the claims, as |
| | dge the duty to disclose inform of Federal Regulations § 1.56 | | examination of this app | lication in accordance with |
| inventor's cer America listed international a | aim foreign priority benefits un tificate or of any PCT internati d below and have also identified application(s) designating at least having a filing date before that | ional application(s) designating designation and below any foreign application ast one country other than the | g at least one country of on(s) for patent or inven United States of Americ | her than the United States of ator's certificate or any PCT |
| PRIOR FOREIGN/PC | CT APPLICATION(S) AND | ANY PRIORITY CLAIMS | UNDER 35 U.S.C. § 1 | 19: |
| | DUNTRY | APPLICATION NUMBER | DATE OF FILING | PRIORITY CLAIMED |
| | indicate "PCT") | AFFLICATION NUMBER | (day, month, year) | UNDER 35 U.S.C. § 119 |
| United States | | 60/112,434 | December 16, 1998 | ¥ YES □ NO |
| | | | | ☐ YES ☐ NO |
| | | | | ☐ YES ☐ NO |
| | | | | ☐ YES ☐ NO |



| Declaration fo | r Patent A | pplication | (Continued) |
|-----------------|------------|-------------|-------------|
| Deciai auton 10 | | Philemeion: | Communica |

(Includes Reference to PCT International Applications)

ATTORNEY'S DOCKET NUMBER 342312003700

We hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this application is

| | acknowled the filing of | lge the duty to late of the pric | disclose mat or application | erial informatio (s) and the natio | nanner provided by the firm n as defined in Title 37, Co onal or PCT international fi | ode of Federal Regul | ations, § 1.56(a) which dication: | occurred between | |
|--|---|-------------------------------------|---|---------------------------------------|---|--|-----------------------------------|------------------|--|
| | OR U.S. APP DER 35 U.S.C | | OR PCT IN | ITERNATION | AL APPLICATIONS DI | ESIGNATING THI | E U.S. FOR BENEFIT | | |
| | | U | .S. APPLICA | TIONS | · · | | STATUS (Check one) | | |
| | U S APPLICATION NUMBER U S F | | FILING DATE | PATENTED | PENDING | ABANDONED | | | |
| | | | | | | | | | |
| PCT APPLICATIONS DESIGNATING THE | | | | GNATING TH | E U.S. | | STATUS (Check one) | | |
| PC | PCT APPLICATION NUMBER PCT FILING DATE | | U S SERIAL NUMBERS ASSIGNED (if any) | PATENTED | PENDING | ABANDONED | | | |
| | | | | | | | | | |
| Send correspondence to: Madeline I. Johnston Morrison & Foerster LLP 755 Page Mill Road Palo Alto, California 94304-10 | | | | | Direct telephone calls to: Madeline I. Johnston at (650) 813-5840 | | | | |
| 201 | 1 2 CAMB VALANCE : : | | | FIRST GIVEN NAME John | | SECOND GIVEN NAME Michael | | | |
| | RESIDENCE & CITIZENSHIP | ciry <u>Indianapol</u> i | s IN | ÷ • | STATE OR FOREIGN COUNTRY Indiana | United States of America | | rica | |
| | POST OFFICE ADDRESS | 1825 Sailing Court | | CITY Indianapolis FIRST GIVEN NAME | | STATE & ZIP CODE/COUNTRY Indiana 46260 SECOND GIVEN NAME | | | |
| 202 | OF INVENTOR | NTOR JAMISON | | James STATE OR FOREIGN COUNTRY | | Andrew Country of Citizenship | | | |
| | CITIZENSHIP Indianapolis IN. | | Indiana | | United States of America | | | | |
| | POST OFFICE ADDRESS 6711 Eagle Point Drive North, Apt. 1C | | | Indianapolis | | Indiana 46254 | | | |
| | believed to punishable | o be true; and e by fine or in | further that the | ese statements or both, under s | y own knowledge are true were made with the knowl ection 1001 of Title 18 of t | edge that willful fals | e statements and the like | e so made are | |
| dox | may jeopa | | dity of the app | | patent issuing thereon. | ` | | · • | |

| and Jeopai caze the validity of the app | nearion of any parent issuing moreon. | _ |
|---|---------------------------------------|-----|
| GNAPTE OF AVENTOR 201 | SIGNATURE OF INVENTOR 202, | . : |
| DART 9/19/01 | DATE 9/18/01 | |

Please direct all written communications relative to this application to:

Madeline I. Johnston

Morrison & Foerster LLP

755 Page Mill Road

Palo Alto, California 94304-1018

Please direct all telephone communications to Madeline I. Johnston at (650) 813-5840.

Eli Lilly and Company an Indiana corporation


Dated:

Name: Douglas K. Norman

Title: Deputy General Patent Counsel

Address: Lilly Corporate Center

Indianapolis, Indiana 46285



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Michael J. RODRIGUEZ, et al.

Serial No.: 09/868,347

371 Filing Date: June 15, 2001

For: CYCLIC PEPTIDE ANTIFUNGAL

AGENTS

Examiner: To Be Assigned

Group Art Unit: To Be Assigned

PROSECUTION BY ASSIGNEE AND POWER OF ATTORNEY UNDER 37 C.F.R. § 3.71


Assistant Commissioner for Patents Washington, D.C. 20231

Dear Sir:

Eli Lilly and Company, the assignee of the entire right, title and interest in this patent application, under 37 C.F.R. § 3.71 hereby appoints:

Lisa A. Amii (Reg No. 48,199) Mehran Arjomand (Reg No. P48,231) Sanjay S. Bagade (Reg No. 42,280) Shantanu Basu (Reg No. 43,318) Vincent J. Belusko (Reg No. 30,820) Kimberly A. Bolin (Reg No. 44,546) Tyler S. Brown (Reg No. 36,465) A. Randall Camacho (Reg No. 46,595) Robert K. Cerpa (Reg No. 39,933) Alex Chartove (Reg No. 31,942) Thomas E. Ciotti (Reg No. 21,013) Matthew M. D'Amore (Reg No. 42,457) Peter Davis (Reg No. 36,119) Stephen C. Durant (Reg No. 31,506) David L. Fehrman (Reg No. 28,600) Thomas George (Reg No. 45,740) Kenneth R. Glick (Reg No. 28,612)

Randolph Ted Apple (Reg No. 36,429) Laurie A. Axford (Reg No. 35,053) Erwin J. Basinski (Reg No. 34,773) Richard R. Batt (Reg No. 43,485) Jonathan Bockman (Reg No. 45,640) Barry E. Bretschneider (Reg No. 28,055) Nicholas Buffinger (Reg No. 39,124) Mark R. Carter (Reg No. 39,131) Peng Chen (Reg No. 43,543) Thomas Chuang (Reg No. 44,616) Cara M. Coburn (Reg No. 46,631) Raj S. Davé (Reg No. 42,465) Karen B. Dow (Reg No. 29,684) Carolyn A. Favorito (Reg No. 39,183) Hector Gallegos (Reg No. 40,614) Debra J. Glaister (Reg No. 33,888) Bruce D. Grant (Reg No. 47,608)



Douglas G. Hodder (Reg No. 41,840) Charles D. Holland (Reg No. 35,196) Peter Hsieh (Reg No. 44,780) Wayne Jaeschke, Jr. (Reg No. 38,503) Parisa Joriani (Reg No. 46,813) Richard C. Kim (Reg No. 40,046) Lawrence B. Kong (Reg No. P49,043) Glenn Kubota (Reg No. 44,197 Michael J. Mauriel (Reg No. 44,226) Philip A. Morin (Reg No. P-45,926) Paul S. Naik (Reg No. P49,075) Martin M. Noonen (Reg No. 44,264) Phillip Reilly (Reg No. 41,415) Terri Shieh-Newton (Reg No. 47,081) Kevin R. Spivak (Reg No. 43,148) Thomas L. Treffert (Reg No. P48,279) Michael R. Ward (Reg No. 38,651) Todd W. Wight (Reg No. 45,218) David T. Yang (Reg No. 44,415) George C. Yu (Reg No. 44,418) Arleen Palmberg (Reg No. 40,422) Charles E. Cohen (Reg No. 34,565)

of Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018, telephone (650) 813-5600, or of Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana 46285 to prosecute this application and transact all matters in the United States Patent and Trademark Office connected therewith, said appointment to be to the exclusion of the inventors and their attorneys in accordance with the provisions of 37 C.F.R. § 3.71 provided that if any one of said attorneys or agents ceases being affiliated with the law firm of Morrison & Foerster as partner, employee or of counsel, such attorney's or agent's appointment as attorney or agent and all powers derived therefrom shall terminate on the date such attorney or agent ceases being so affiliated.

ASSIGNMENT

WHEREAS we, Michael John RODRIGUEZ and James Andrew JAMISON (hereinafter referred to as the assignors), residing at 1825 Sailing Court, Indianapolis, Indiana 46260, and 6711 Eagle Point Drive North, Apartment 1C, Indianapolis, Indiana 46254 have made an invention which is the subject of a Patent Cooperation Treaty ("PCT") patent application entitled CYCLIC PEPTIDE ANTIFUNGAL AGENTS, PCT/US09/868,347, filed June 15, 2001 ("Application"); and

WHEREAS ELI LILLY AND COMPANY, an Indiana corporation having its principal place of business at Lilly Corporate Center, Indianapolis, Indiana 46285, wishes to acquire the entire interest in all inventions disclosed in such Application;

NOW, THEREFORE, in consideration of good and valuable consideration, the receipt of which is hereby acknowledged, we hereby sell, assign, transfer and set over unto Eli Lilly and Company, its successors and assigns (collectively "Lilly") our entire right, title and interest in, to and under the Application, including all priority rights for other countries arising therefrom, all inventions therein disclosed, and any and all present or future patent applications to such inventions that may be filed in the United States or inclusive of, but not limited to, continuations, any foreign country, continuations-in-part, substitutions, reexaminations, reissues, divisions, international applications under the Patent Cooperation Treaty ("PCT"), United States provisional patent applications, certificates of addition, utility models, petty patents, as well as all other intellectual property related to the Application, inclusive of, but not limited to, supplementary protection certificates, copyrights, trademarks, and data package exclusivity rights; and any and all Letters Patent of the United States and of all foreign countries and all related patent term extensions which may be granted for Letters Patent with respect to the Application; all of the above to be held and enjoyed by Lilly for its own use and enjoyment to the full end of the term or terms for which such Letters Patent and related intellectual property rights may be granted, as fully and entirely as the same would have been held and enjoyed by us had this Assignment and sale to Lilly not been made.

For ourselves and for our heirs, successors and legal representatives, we covenant that no assignment, sale, agreement or encumbrance has been or will be made or entered into which would conflict with this Assignment.

For ourselves and for our heirs, successors and legal representatives, we further covenant and agree with Lilly that upon request we and they will, without further consideration than that now paid, but at the expense of Lilly: (i) execute original, provisional, substitute, continuation, divisional, continuation-in-part, reexamined, or reissued applications, amended specifications, or rightful declarations or oaths for such application; (ii) communicate to Lilly any facts known to us or them relating to such inventions or the history thereof; (iii) execute preliminary statements and testify in any

interference proceedings, litigation discovery proceedings and depositions, oppositions, cancellation proceedings, priority contests, public use proceedings, administrative agency proceedings, litigation and other court actions and the like; (iv) execute and deliver any application papers, affidavits, declarations, assignments, or other instruments; and (v) do all other acts which, in the opinion of counsel for Lilly, may be necessary or desirable to secure the grant of Letters Patent and related intellectual property to Lilly or its nominees, in the United States and in all other countries where Lilly may desire to have such inventions, or any of them, patented, with specifications and claims in such form as shall be approved by counsel for Lilly and to vest and confirm in Lilly or its nominees the full and complete legal and equitable title to all such Letters Patent and related intellectual property.

| IN | WITNESS | WHEREOF | we have | executed | this as | ssignment | on the | e date |
|-----------------------------|------------------|------------|---------|------------|-------------------|-----------|-------------|-----------------|
| indicated belo | w. | | | 1 10 1 | \mathcal{D}_{n} | | | |
| Sept. 19,7 | 1001 | | | hepen | Tolly | | | |
| Date | | | Micha | el John Re | DRIGUE |]. | | - |
| | | | 40 | me Mudde | n Flee | | | |
| • | | | James | Andrew J | MISON | | | - |
| | | | 0 | | | | | |
| | | | | | | | | |
| STATE OF INDIA | ANA |)) ss: | | | | | | |
| COUNTY OF MAR | ION |) 55: | | | | | | |
| | | | | • | | | | |
| | | _ | | r Johnson | _ | | | ndiana, |
| personally are acknowledged | | | | | | | | ON and ay of |
| | <u>ben</u> , 200 | | | _ | | | | - |
| , | | | (| 0.0 | αK | حفدين | | |
| | | | Wata | ry Public | <u> </u> | | | |
| My commission | expires: | | Notal | Thum, v. | | | | |
| <u> </u> | _ | | | | | | | |
| 5-10-9 | >7 | | | | | | | |